Table 2.

Associations between the three most significant SNPs in 8q24 cancer risk regions and serum testosterone measures in 563 male subjects

Serum androgenSNP (major/minor alleles)Location (bp)MAF*βSEPPP§
Total testosteroners12334903 (C)128,119,6950.40−0.100.038.69 × 10−40.0230.100
rs1456310 (A)128,121,6150.43−0.100.031.13 × 10−30.0300.127
rs980171 (G)128,123,7040.39−0.110.033.14 × 10−49.60 × 10−30.039
Bioavailable testosteroners12334903 (C)128,119,6950.40−0.090.033.73 × 10−40.0120.049
rs1456310 (A)128,121,6150.43−0.080.026.28 × 10−40.0190.076
rs980171 (G)128,123,7040.39−0.090.031.66 × 10−44.95 × 10−30.023
  • *MAF, minor allele frequency.

  • Based on age-adjusted linear regression analysis of log-transformed androgen and SHBG measurements using SNPs in an additive genetic model.

  • Adjusted for multiple comparisons using a parametric bootstrap procedure with 20,000 replicates generated under the null for the evaluation of significance levels accounting for all 38 SNPs tested within prostate cancer region 2.

  • §Adjusted for multiple comparisons using a parametric bootstrap procedure with 20,000 replicates generated under the null for the evaluation of significance levels accounting for all 164 SNPs tested in the 8q24 region.